Toxicity Profiles
Toxicity Summary for NITROBENZENE
NOTE:
Although the toxicity values presented in these toxicity profiles
were correct at the time they were produced, these values are subject to change.
Users should always refer to the
Toxicity Value Database
for the current toxicity values.
Download a WordPerfect version of this toxicity profile. Please note that this document has been saved in WordPerfect 5.1/5.2 for greater accessibility but may have been originally formatted in later versions of WordPerfect (i.e., WordPerfect 6.1, Suite 7, etc.); therefore, formatting changes (i.e., Contents and Page Numbering) may occur when downloading this document.
- EXECUTIVE SUMMARY
- 1. INTRODUCTION
- 2. METABOLISM AND DISPOSITION
- 2.1 ABSORPTION
2.2 DISTRIBUTION
2.3 METABOLISM
2.4 EXCRETION
- 3. NONCARCINOGENIC HEALTH EFFECTS
- 3.1 ORAL EXPOSURES
3.2 INHALATION EXPOSURES
3.3 OTHER ROUTES OF EXPOSURE
3.4 TARGET ORGANS/CRITICAL EFFECTS
- 4. CARCINOGENICITY
- 4.1 ORAL EXPOSURES
4.2 INHALATION EXPOSURES
4.3 OTHER ROUTES OF EXPOSURE
4.4 EPA WEIGHT-OF-EVIDENCE
4.5 CARCINOGENICITY SLOPE FACTORS
- 5. REFERENCES
MARCH 1993
Prepared by: Rosmarie A. Faust, Ph.D., Chemical Hazard Evaluation Group,
Biomedical Environmental Information Analysis Section, Health and Safety Research Division,
*, Oak Ridge, Tennessee.
Prepared for: Oak Ridge Reservation Environmental Restoration Program.
*Managed by Martin Marietta Energy Systems, Inc., for the U.S. Department of Energy under
Contract No. DE-AC05-84OR21400.
EXECUTIVE SUMMARY
Nitrobenzene (CAS Reg. No. 98-95-3) is a pale yellow liquid with an odor of bitter almonds
(Dunlap, 1981). Most of the nitrobenzene produced is used as an intermediate in the synthesis of
aniline. An anthropogenic environmental contaminant, nitrobenzene can be released to wastewater
and air from industrial sources (ATSDR, 1990). It is primarily removed from the environment by
photolysis, reaction with hydroxyl radicals, volatilization, and biodegradation (U.S. EPA, 1985).
Nitrobenzene can be absorbed by humans following oral, inhalation, or dermal exposure
(U.S. EPA, 1980). When absorbed into the blood, nitrobenzene oxidizes the iron in hemoglobin to
form methemoglobin, thus decreasing the oxygen carrying capacity of the blood. The primary
systemic effect associated with human exposure to nitrobenzene is methemoglobinemia. Acute oral
exposure has resulted in methemoglobinemia, cyanosis, and anemia, and neurological effects,
including headache, nausea, vertigo, confusion, unconsciousness, apnea, coma, and death
(Piotrowski, 1967; U.S. EPA, 1980; ATSDR, 1990). Methemoglobinemia has also been reported
following subchronic to chronic occupational exposure to nitrobenzene. Additional effects included
sulfhemoglobinemia, presence of Heinz bodies in erythrocytes, liver toxicity (hepatomegaly,
jaundice, and altered serum chemistry), spleen enlargement, and neurological symptoms (headache,
nausea, weakness, vertigo, numbness of legs, and hyperalgesia of hands and feet) (U.S. EPA, 1980;
Ikeda and Kita, 1964). Dermal exposure to nitrobenzene has resulted in contact dermatitis
(Beauchamp et al., 1982).
Effects observed in subchronic inhalation studies with rodents exposed to nitrobenzene at
concentrations up to 50 ppm for 90 days included methemoglobinemia, splenic lesions
(splenomegaly, increased hemosiderosis and hematopoiesis), liver toxicity (hepatocyte hyperplasia
and focal necrosis), kidney nephrosis, and testicular degeneration. Morphologic changes of the
adrenal cortex were reported for mice (CIIT, 1984). Effects on the spleen, kidneys, and liver were
also reported in rodents exposed to concentrations up to 125 ppm for 14 days. In addition, there was
morphologic damage to the hind brain (Medinsky and Irons, 1985). Testicular degeneration and
decreased sperm levels were reported in a two-generation reproductive study with rats (Dodd et al.,
1987).
A reference dose (RfD) of 5E-3 mg/kg/day for subchronic oral exposure and 5E-4
mg/kg/day for chronic oral exposure to nitrobenzene was calculated from a lowest-observed-adverse-effect level (LOAEL) of 25 mg/m3 derived from a 90-day inhalation study with F344 rats
and B6C3F1 mice (CIIT, 1984). The critical effects were hematological changes in F344 rats, and
adrenal, renal, and hepatic lesions in B6C3F1 mice (U.S. EPA, 1992a,b). Because this value is based
on a route to route extrapolation, the RfD may change pending further review by EPA (U.S. EPA,
1992a). The same study (CIIT, 1984) served as the basis of a reference concentration (RfC) of 2E-2
mg/m3 for subchronic inhalation exposure and 2E-03 mg/m3 for chronic inhalation exposure to
nitrobenzene (U.S. EPA, 1992b). This value is currently under review by an EPA work group (U.S.
EPA, 1992a).
No suitable cancer bioassays or epidemiological studies are available to assess the
carcinogenicity of nitrobenzene. Therefore, U.S. EPA (1992a,b) has placed nitrobenzene in weight-of-evidence group D, not classifiable as to human carcinogenicity.
1. INTRODUCTION
Nitrobenzene (CAS Reg. No. 98-95-3), also known as nitrobenzol or oil of mirbane, is a pale
yellow liquid with an odor of bitter almonds (Dunlap, 1981). The compound's characteristic odor
can be detected in water at a threshold concentration as low as 30 g/L (U.S. EPA, 1980).
Nitrobenzene has a melting point of 5.85C and a boiling point of 210.9C. It is slightly soluble in
water, readily soluble in organic solvents such as alcohol, ether, and benzene (Dunlap, 1981), and
very soluble in lipids. Nitrobenzene is prepared by direct nitration of benzene in the presence of
nitric and sulfuric acids (U.S. EPA, 1980). About 98% of all nitrobenzene produced is used in the
synthesis of aniline; the major use of aniline is in the manufacture of polyurethanes. Nitrobenzene
is also used as a solvent and in the refining of some lubricating oils, in the manufacture of cellulose
ethers and acetate, as a chemical intermediate in the synthesis of N-acetyl p-aminophenol (Tylenol®)
and other chemicals, as a flavoring agent, a perfume for soaps, and as a solvent for shoe dyes
(Beauchamp et al., 1982; Beard and Noe, 1981; U.S. EPA, 1985; ATSDR, 1990).
An anthropogenic environmental contaminant, nitrobenzene can be released to wastewater
and air from industrial sources. Nitrobenzene is formed in ambient air, particularly in urban areas,
as a result of photochemical reactions of nitrogen oxides with benzene derived from automobile
fuels (ATSDR, 1990). Photolysis, volatilization, and biodegradation are significant removal
processes affecting the fate of nitrobenzene in water. Reaction with hydroxyl radicals and photolysis
appear to be the primary removal mechanisms in ambient air (U.S. EPA, 1985). Principal
degradation products of nitrobenzene in air include p-nitrophenol and nitrosobenzene (ATSDR,
1990).
2. METABOLISM AND DISPOSITION
2.1. ABSORPTION
Although nitrobenzene can be absorbed by the gastrointestinal tract, it is most commonly
absorbed through the respiratory tract and skin (U.S. EPA, 1980, 1985). Humans breathing air
containing 5-30 g nitrobenzene/L retained approximately 80% in the respiratory tract, and the
amount of retained nitrobenzene remained fairly constant over a period of 6 hours (Beauchamp et
al., 1982). Humans exposed to 5 mg/m3 for 6 hours absorbed 18 mg through the lungs and 7 mg
through the skin (Piotrowski, 1967). Nitrobenzene can be absorbed through the skin in both vapor
and liquid state. The rate of vapor absorption depends on the air concentration, ranging from 1
mg/hr at 5 mg/m3 to 9 mg/hr at 30 mg/m3. Air temperature does not affect dermal absorption rates,
but an increase in humidity from 33 to 67% will increase the absorption rate by 40%. Maximal
dermal absorption of liquid nitrobenzene was 0.2-3 mg/cm2/hr, depending on skin temperature.
Absorption was increased with elevated skin temperature and duration of contact (Piotrowski, 1977).
Based on toxic responses observed in mice and rabbits following skin application, nitrobenzene
appears to be absorbed in dermally treated animals (ATSDR, 1990).
2.2. DISTRIBUTION
No studies were available concerning the tissue distribution of nitrobenzene in humans.
Two days after gavage administration of 0.25 mL of radiolabeled nitrobenzene to rabbits,
approximately 54% of the radioactivity was found in tissues, accumulating primarily in adipose
tissue and the intestinal tract. Eight days following dosing, 8% of the radioactivity remained in the
animals, mostly in adipose tissue (Parke, 1956). An oral study with rats showed that nitrobenzene
is bound to blood, liver, kidneys, and lungs one day after administration by gavage. Nitrobenzene
metabolites were shown to be bound to blood proteins, both in hemoglobin and in plasma (Albrecht
and Neumann, 1985). One hour after intravenous administration of nitrobenzene to rats, the ratio
of the concentration of nitrobenzene in adipose tissue vs. blood in internal organs and muscle was
10:1 (Piotrowski, 1977). No studies were found addressing the distribution of nitrobenzene
following inhalation or dermal exposure.
2.3. METABOLISM
The metabolites identified and measured in the urine of humans exposed to nitrobenzene
indicate that metabolism proceeds by a series of oxidation (hydroxylation) and reduction reactions,
resulting primarily in the excretion of p-nitrophenol and p-aminophenol (Beauchamp et al., 1982).
Numerous metabolites have been identified in the urine of laboratory animals. Following
gavage administration of radiolabeled nitrobenzene to rabbits, Parke (1956) recovered 1% of a 250-mg/kg dose as CO2, and 0.6% was exhaled as unchanged nitrobenzene. The total excretion of
radioactivity in the expired air, urine, and feces accounted for nearly 70% of the dose 4-5 days after
administration of nitrobenzene. p-Aminophenol in the urine accounted for 31% of the administered
radioactivity within 4 or 5 days after dosing. Smaller amounts of m-aminophenol, o-aminophenol,
p-nitrophenol, and m-nitrophenol, each comprising 3-9% of the administered radioactivity, were also
identified in the urine. Less than 1% of the radioactivity was identified as aniline, o-phenol, o-nitrophenol, 4-nitrocatechol, nitroquinol, or p-nitrophenylmercapturic acid.
Human and animal studies have shown that nitrobenzene is involved in the formation of
methemoglobin, resulting in methemoglobinemia. Although not completely understood, reduced
nitrobenzene metabolites are believed to be responsible for nitrobenzene-induced
methemoglobinemia. Studies with rats and mice demonstrated that orally administered nitrobenzene
is reduced in the intestinal tract and that intestinal microfloral metabolism is essential for the
production of methemoglobin (Goldstein et al., 1984; Albrecht and Neumann, 1985).
2.4. EXCRETION
Urinary excretion appears to be the major route of nitrobenzene elimination in humans after
oral or inhalation exposure. In most cases of oral nitrobenzene poisoning, the metabolites p-aminophenol and p-nitrophenol were excreted in the urine (ATSDR, 1990). Ikeda and Kita (1964)
identified the same two metabolites in the urine of a woman who had been occupationally exposed
to nitrobenzene for 17 months. In volunteers who had inhaled 6 ppm nitrobenzene for 6 hours, the
urinary excretion of p-nitrophenol was most rapid during the first two hours following exposure.
The metabolite was still detectable 100 hours after cessation of exposure (Salmova et al., 1963).
Following oral administration of radiolabeled nitrobenzene to rabbits, Parke (1956)
recovered only small amounts of a 250-mg/kg dose as CO2 or as unchanged compound in expired
air. The total excretion of radioactivity in the expired air, urine, and feces accounted for nearly 70%
of the dose 4-5 days after administration of nitrobenzene. Urinary radioactivity was still detected
ten days after dosing. Delayed excretion was also apparent in a more recent gavage study with rats
(Albrecht and Neumann, 1985). One day after treatment, 50% of the dose appeared in the urine and
4% in the feces; after the fifth day, 65% of the dose appeared in the urine and 16% in the feces. A
gavage study with rabbits showed that all phenolic compounds were excreted in conjugated form
as glucuronide or sulfate (Beauchamp et al., 1982). Bile is a minor route of excretion of
nitrobenzene and its metabolites in rats; 2-4% of an oral dose was excreted by this route in 12 hours
(Rickert et al., 1983). Ikeda and Kita (1964) identified p-aminophenol and p-nitrophenol in the urine
of rats that had been exposed to nitrobenzene by inhalation.
3. NONCARCINOGENIC HEALTH EFFECTS
3.1. ORAL EXPOSURES
3.1.1. Acute Toxicity
3.1.1.1. Human
Acute effects have been reported following accidental or intentional ingestion of liquid
nitrobenzene or false bitter almond oil in food or medicine (U.S. EPA, 1980). Following absorption
into the blood, nitrobenzene oxidizes the iron in hemoglobin to form methemoglobin, thus
decreasing the oxygen carrying capacity of the blood. Methemoglobinemia with resulting cyanosis
is the most characteristic symptom of nitrobenzene poisoning in humans. If cyanosis is severe or
prolonged, coma and death may occur. Anemia may be seen 1-2 weeks after acute poisoning as a
result of the hemolytic effect of nitrobenzene (Piotrowski, 1967; U.S. EPA, 1980). Neurological
effects, including headache, nausea, vertigo, confusion, unconsciousness, apnea, and coma have
been reported following ingestion of nitrobenzene (ATSDR, 1990). However, no data were
available to reliably estimate the levels of nitrobenzene associated with methemoglobinemia or
neurological effects.
3.1.1.2. Animal
Smyth et al. (1969) reported an LD50 of 600 mg/kg in rats. Damage to the brain stem,
cerebellum, and fourth ventricle was reported in male rats following administration of a single 50-
mg/kg dose of nitrobenzene (Morgan et al., 1985). Histopathologic lesions of the liver and testes
were consistently observed in male F344 rats given single oral doses of nitrobenzene (Bond et al.,
1981). Hepatocellular nucleolar enlargement was seen after administration of 110 mg/kg, the lowest
dose tested, while hepatic centrilobular necrosis occurred in all rats receiving 450 mg/kg and in
some receiving the lower doses of nitrobenzene. Testicular lesions developed within one to four
days after administration of 300-450 mg/kg; one rat exhibited a cerebellar lesion at 450 mg/kg. Oral
administration of 200-600 mg nitrobenzene/kg to rats resulted in methemoglobinemia. Diet has
been shown to affect the production of methemoglobin by influencing the intestinal microflora
(Goldstein et al., 1984).
3.1.2. Subchronic Toxicity
Information on the subchronic oral toxicity of nitrobenzene in humans or animals was not
available.
3.1.3. Chronic Toxicity
Information on the chronic oral toxicity of nitrobenzene in humans or animals was not
available.
3.1.4. Developmental and Reproductive Toxicity
3.1.4.1. Human
Information on the developmental or reproductive toxicity of nitrobenzene in humans
following oral exposure was not available.
3.1.4.2. Animal
A single oral dose of 300 mg/kg nitrobenzene produced a transient decrease of sperm
production and testicular degeneration in rats (Levin et al., 1988). Testicular lesions in rats,
confined to the seminiferous tubules with necrosis of primary and secondary spermatocytes and
appearance of multi-nucleated giant cells, developed within one to four days following
administration of 300-450 mg nitrobenzene/kg (Bond et al., 1981).
3.1.5. Reference Dose
3.1.5.1. Subchronic
ORAL RfDs: 5E-3 mg/kg/day (U.S. EPA, 1992b)
UNCERTAINTY FACTOR: 1000
NOAEL: None
LOAEL: 25 mg/m3, converted to 4.6 mg/kg/day
PRINCIPAL STUDY: CIIT, 1984
COMMENTS: The same study (Section 3.2.2.2) applies to both the subchronic and chronic RfD
derivations. The LOAEL was based on hematologic effects in F344 rats and on adrenal, renal,
and hepatic lesions in B6C3F1 mice exposed by inhalation to 25 mg/m3 of nitrobenzene for 90
days. The uncertainty factor of 1000 includes two factors of 10 for intra- and interspecies
variability and a factor of 10 for estimating an effect from a LOAEL rather than a NOAEL (U.S.
EPA, 1992a).
3.1.5.2. Chronic
ORAL RfD: 5E-4 mg/kg/day (U.S. EPA, 1992a)
UNCERTAINTY FACTOR: 10,000
NOAEL: None
LOAEL: 25 mg/m3, converted to 4.6 mg/kg/day
CONFIDENCE:
Study: Medium
Data Base: Low
RfD: Low
VERIFICATION DATE: 07/08/85
PRINCIPAL STUDY: CIIT, 1984
COMMENTS: The LOAEL was based on hematologic effects in F344 rats and on adrenal, renal,
and hepatic lesions in B6C3F1 mice exposed by inhalation to 25 mg/m3 of nitrobenzene for 90
days. The LOAEL was converted to mg/kg/day by multiplying by the following factors: 6 hr/24
hr x 5 days/7 days (adjustment for discontinuous exposure); 0.039 cm3/day/0.03 kg (mouse
breathing rate/body weight); and 0.8 (absorption). The uncertainty factor of 10,000 includes two
factors of 10 for intra- and interspecies variability, a factor of 10 for estimating an effect from
a LOAEL rather than a NOAEL, and a factor of 10 for extrapolation from subchronic to chronic
exposure. Because the RfD is based on route to route extrapolation, the value may change
pending further review by EPA (U.S. EPA, 1992a).
3.2. INHALATION EXPOSURES
3.2.1. Acute Toxicity
3.2.1.1. Human
Methemoglobinemia has been reported after acute, short-term occupational exposure to
nitrobenzene. Additional effects include sulfhemoglobinemia and anemia (Beauchamp et al., 1982;
U.S. EPA, 1985). OSHA (1978) reported that human exposure to nitrobenzene vapor at
concentrations of 6 ppm resulted in headache, vertigo, and a low degree of methemoglobinemia;
exposure to 40 ppm caused intoxication. Alcohol has the potential to enhance the toxicity of
nitrobenzene. For example, ingestion of an alcoholic beverage induced immediate acute symptoms,
including coma, in a worker who had apparently recovered from the effects of chronic nitrobenzene
exposure (U.S. EPA, 1980).
3.2.1.2. Animal
Inhalation of air saturated with nitrobenzene for 5.5 hours induced nystagmus and paralysis in dogs
(Beauchamp et al., 1982).
3.2.2. Subchronic Toxicity
3.2.2.1. Human
Ikeda and Kita (1964) reported neurotoxic and hepatotoxic effects in a 47-year-old woman who
had been occupationally exposed to nitrobenzene for 17 months. The effects included headache,
nausea, vertigo, general weakness, numbness of legs, hyperalgesia of hands and feet, cyanosis,
hypotension, spleen enlargement, liver enlargement and tenderness, jaundice, and altered serum
chemistry.
3.2.2.2. Animal
In a subchronic inhalation study, F344 rats, CD rats, and B6C3F1 mice were exposed to
nitrobenzene at concentrations of 0, 25, 81, or 252 mg/m3 (0, 5, 16, or 50 ppm) 6 hours/day, 5
days/week for 90 days (CIIT, 1984). In both strains of rats, there were concentration-related
increased levels of methemoglobin; increased hemosiderosis and hematopoiesis of the spleen; toxic
nephrosis of the kidneys; and liver lesions, increasing in severity from hepatocellular hypertrophy
to focal necrosis. At 25 mg/m3, the incidence of spleen, kidney, and liver lesions was similar to
controls. At 81 mg/m3, rats exhibited changes in hematological parameters indicative of hemolytic
anemia, and increased spleen and liver weights. At 252 mg/m3, male rats exhibited decreased
testicular weights, severe degeneration of the testicular spermatogenic epithelium, and bilateral
testicular atrophy. A low incidence of these testicular lesions was also seen at 25 and 81 mg/m3.
In mice, the lowest concentration caused increased hemosiderosis of the spleen, which became more
severe at higher concentrations. Female mice exposed to 25 mg/m3 had increased incidences and
severity of vacuolization of the zona reticularis of the adrenal gland. Mice also had hepatocellular
hyperplasia at 81 mg/m3 and increased liver and spleen weights and methemoglobinemia at 252
mg/m3.
Strain and sex differences in response to nitrobenzene exposure were demonstrated in studies
conducted by Medinsky and Irons (1985). F344 rats, CD rats, and B6C3F1 mice were exposed to
concentrations of nitrobenzene ranging from 10 to 125 ppm for 14 days. At 125 ppm, there was
40% mortality in CD rats, and morbidity necessitated the sacrifice of nearly all mice before the end
of the exposure period. F344 rats, however, tolerated this concentration without any clinical signs
of toxicity. Histological renal lesions were seen at 125 ppm and included hydropic degeneration of
the cortical tubular cells in 20% of male and 90% of female CD rats, and hyaline nephrosis in 100%
of male and in 20% of female F344 rats. In mice, multifocal degenerative changes of the tubular
epithelium was observed in males at 35 ppm, but not at the higher concentrations. Species- and sex-related differences in liver pathology were also observed in animals exposed to 125 ppm: severe
centrilobular necrosis and degeneration occurred in male mice but not in female mice; in CD rats,
the hepatic effects were similar but not as severe; and no significant liver lesions were seen in F344
rats. Splenic lesions, such as sinusoidal congestion, increased extramedullary hematopoiesis,
hemosiderin-laden macrophages, infiltration of red pulp, and presence of proliferative capsular
lesions, were present to varying degrees in all three species and exposure groups. Brain lesions
(damage to the hindbrain, including bilateral cerebellar perivascular hemorrhage and malacia), was
observed in both sexes of CD rats and in mice exposed to 125 ppm.
3.2.3. Chronic Toxicity
3.2.3.1. Human
Chronic toxic effects in humans usually result from industrial exposure to nitrobenzene vapor that
is absorbed through the lungs or the skin (U.S. EPA, 1980). Recorded symptoms include cyanosis,
methemoglobinemia, jaundice, anemia, sulfhemoglobinemia, presence of Heinz bodies in the
erythrocytes, and dark colored urine (U.S. EPA, 1980).
3.2.3.2. Animal
3.2.4. Developmental and Reproductive Toxicity
3.2.4.1. Human
Dorigan and Hushon (1976) reported chorionic and placental changes in pregnant women who used
nitrobenzene in the production of a rubber catalyst. Also reported were menstrual disturbances after
chronic exposure.
3.2.4.2. Animal
Tyl et al. (1987) exposed pregnant CD rats to 0, 1, 10, or 40 ppm nitrobenzene, 6 hours/day on
gestational days 5 through 15. Exposure to nitrobenzene did not result in developmental effects at
any exposure concentration. However, maternal toxicity was observed; absolute and relative spleen
weights were increased at 10 and 40 ppm, and weight gain was reduced at 40 ppm, with full recovery
after cessation of exposure.
Dodd et al. (1987) conducted a two-generation reproductive study by exposing CD rats to 1, 10,
or 40 ppm nitrobenzene for 4 weeks. No compound-related effects on reproduction were observed
at 1 or 10 ppm. In litters derived from rats exposed to 40 ppm, there was a decrease of fertility
indices of the F0 and F1 generations, associated with atrophy of seminiferous tubules, spermatocyte
degeneration, and reduced testicular and epididymal weights. Other reproductive parameters
remained unaltered and maternal toxicity was not observed. Testicular atrophy, degeneration of
seminiferous tubules, and a reduction or absence of mature sperm in the epididymis was also
reported in F344 and CD rats exposed to 50 ppm nitrobenzene for 90 days (CIIT, 1984).
3.2.5. Reference Concentration
3.2.5.1. Subchronic
INHALATION RfCs: 2E-2 mg/m3 (6E-4 mg/kg/day) (U.S. EPA, 1992b)
UNCERTAINTY FACTOR: 1000
NOAEL: None
LOAEL: 25 mg/m3
PRINCIPAL STUDY: CIIT, 1984
COMMENTS: The same study applies to both the subchronic and chronic RfC derivations and was
used for the derivation of the oral RfD (see Sections 3.1.5. and 3.2.2.2). The uncertainty factor of
1000 includes two factors of 10 for intra- and interspecies variability and a factor of 10 for
estimating an effect from a LOAEL rather than a NOAEL. The RfC was derived from methodology
(dose conversions from mg/kg/day to mg/m3) that is not current with the interim inhalation
methodology used by the RfD/RfC Work Group (U.S. EPA, 1992b).
3.2.5.2 Chronic
INHALATION RfC: 2E-3 mg/m3 (6E-4 mg/kg/day) (U.S. EPA, 1992b)
UNCERTAINTY FACTOR: 10,000
NOAEL: None
LOAEL: 25 mg/m3
PRINCIPAL STUDY: CIIT, 1984
COMMENTS: The uncertainty factor of 10,000 includes two factors of 10 for intra- and
interspecies variability, a factor of 10 for estimating an effect from a LOAEL rather than a
NOAEL, and a factor of 10 for extrapolation from subchronic to chronic exposure. The RfC was
derived from methodology (dose conversions from mg/kg/day to mg/m3) that is not current with
the interim inhalation methodology used by the RfD/RfC Work Group (U.S. EPA, 1992b). The
RfC, not currently available in IRIS, is under review by an EPA work group (U.S. EPA, 1992a).
3.3. OTHER ROUTES OF EXPOSURE
3.3.1. Acute Toxicity
3.3.1.1. Human
Contact dermatitis has been reported in workers who used nitrobenzene as a preservative in cutting
oils (Beauchamp et al. (1982).
3.3.1.2. Animal
U.S. EPA (1980) reported dermal and intraperitoneal LD50 values of 2100 mg/kg and 640 mg/kg,
respectively, for rats. According to Shimkin (1939), methemoglobinemia occurred in mice within
3 hours following dermal application of nitrobenzene (concentration not reported). Also observed
was diffuse necrosis of the liver and slight swelling of glomeruli and tubular epithelium.
3.3.2. Subchronic Toxicity
3.3.2.1. Human
Information on the subacute toxicity of nitrobenzene by other routes of exposure in humans was
not available.
3.3.2.2. Animal
Rabbits that received a subcutaneous dose of 840 mg nitrobenzene/kg/day for 3 months exhibited
a decrease of erythrocytes and hemoglobin content soon after treatment started; the values increased
during the three months of treatment but did not return to normal levels during this time period
(Yamada, 1958).
3.3.3. Chronic Toxicity
Information on the chronic toxicity of nitrobenzene by other routes of exposure in humans or
animals was not available.
3.3.4. Developmental and Reproductive Toxicity
3.3.4.1. Human
Information on the developmental or reproductive toxicity of nitrobenzene in humans by other
routes of exposure was not available.
3.3.4.2. Animal
An abstract of a Russian study (Kazanina, 1968) reported delayed embryogenesis, disorders of
organogenesis, and alterations in placentation in rats injected subcutaneously with 125 mg/kg/day
of nitrobenzene during preimplantation and placentation periods.
3.4. TARGET ORGANS/CRITICAL EFFECTS
3.4.1. Oral Exposures
3.4.1.1. Primary Target Organ(s)
1. Blood: Methemoglobinemia in humans resulting in reduced oxygen carrying capacity of the
blood and cyanosis has been reported following accidental or intentional ingestion of
nitrobenzene, however, chronic exposure data were not available. Anemia may occur as a result
of the hemolytic effect of nitrobenzene. Single oral doses of nitrobenzene induced
methemoglobinemia in rats.
2. Nervous system: Chronic exposure data were not available. In humans, headache, nausea,
vertigo, confusion, unconsciousness, apnea, and coma were reported following acute oral
exposure to nitrobenzene. Single oral doses produced pathologic changes of the brain in rats.
3. Liver: Chronic exposure data were not available. Liver enlargement and necrosis were
reported in rats that received single oral doses of nitrobenzene.
4. Testis: Chronic exposure data were not available. Single oral doses of nitrobenzene produced
testicular lesions and a transient decrease of sperm production in rats.
3.4.1.2. Other Target Organ(s)
Information concerning other target organs following oral exposure to nitrobenzene was not
identified.
3.4.2. Inhalation Exposures
3.4.2.1. Primary Target Organ(s)
1. Blood: Nitrobenzene-induced methemoglobinemia resulting in reduced oxygen capacity of
the blood and cyanosis has been reported following short-term, subchronic, and chronic
exposure. Also reported in occupational exposures were anemia, sulfhemoglobinemia, and
presence of Heinz bodies in erythrocytes. Methemoglobinemia occurred in rodents following
subchronic exposure.
2. Nervous system: Occupational exposure to nitrobenzene has resulted in headache, nausea,
vertigo, general weakness, numbness of legs, and hyperalgesia of hands and feet. Pathologic
changes of the brain were reported in a subchronic animal study.
3. Liver: Evidence of liver toxicity (liver enlargement, jaundice, and altered serum chemistry)
has been reported following occupational exposure. In animals, hepatic effects including liver
enlargement, hepatocyte hyperplasia, hepatocyte necrosis, pigmentation of Kupffer cells,
periportal basophilia, and enlarged nucleoli have been reported following subchronic exposure.
4. Testis: Testicular damage (atrophy and degeneration of spermatogenic epithelium) and a
reduction of mature germ cells have been reported in animals following subchronic exposure.
5. Reproduction: Chorionic and placental changes as well as menstrual disturbances have been
reported in women occupationally exposed to nitrobenzene.
6. Spleen: Increased spleen weights with hemosiderin deposits and extramedullary
hematopoiesis have been reported in animals after subchronic exposure to nitrobenzene.
3.4.2.2. Other Target Organ(s)
1. Kidneys: Observed kidney effects following subchronic exposure to nitrobenzene included
increased kidney weights, degeneration of the cortical tubules, and hyaline nephrosis.
2. Adrenal gland: Pathologic changes of the adrenal cortex were reported in mice following
subchronic exposure to nitrobenzene.
3.4.3. Other Routes of Exposure
3.4.3.1. Primary Target Organs
1. Blood: Chronic exposure data were not available. Dermal applications of nitrobenzene
produced methemoglobinemia in mice. Decreased erythrocyte counts and hemoglobin values
were reported in rabbits subcutaneously injected with nitrobenzene.
2. Liver: Chronic exposure data were not available. Dermal applications of nitrobenzene caused
necrosis of the liver in animals.
3. Reproduction: Chronic exposure data were not available. Subcutaneous administration of
nitrobenzene caused delayed embryogenesis, alterations of normal placentation, and abnormalities
in the fetus of rats.
4. Skin: Chronic exposure data were not available. Contact dermatitis has been reported
following dermal occupational exposure to nitrobenzene.
3.4.3.2. Other Target Organs
Kidneys: Chronic exposure data were not available. Dermal applications of nitrobenzene
produced a slight swelling of the glomeruli and tubular epithelium in animals.
4. CARCINOGENICITY
4.1. ORAL EXPOSURES
Information on the carcinogenicity of nitrobenzene in humans or animals following oral exposure
was not available.
4.2. INHALATION EXPOSURES
Information on the carcinogenicity of nitrobenzene in humans or animals following inhalation
exposure was not available.
4.3. OTHER ROUTES OF EXPOSURE
Information on the carcinogenicity of nitrobenzene in humans or animals following other routes
of exposure was not available.
4.4. EPA WEIGHT-OF-EVIDENCE
Classification D -- Not classifiable as to human carcinogenicity (U.S. EPA, 1992a,b).
Basis -- Based on the lack of human or animal data.
4.5. CARCINOGENICITY SLOPE FACTORS
Data were insufficient to derive carcinogenicity slope factors.
5. REFERENCES
Albrecht, W. and H.-G. Neumann. 1985. Biomonitoring of aniline and nitrobenzene: Hemoglobin
binding in rats and analysis of adducts. Arch. Toxicol. 57: 1-5. (Cited in ATSDR, 1990).
ATSDR (Agency for Toxic Substances and Disease Registry). 1990. Toxicological Profile for
Nitrobenzene. Prepared by Life Systems, Inc., under Subcontract to Clement Associates, Inc., for
ATSDR, U.S. Public Health Service under Contract 205-88-0608. ATSDR/TP-90-19.
Beard, R.R. and J.T. Noe. 1981. Aromatic nitro and amino compounds. In: Clayton, G.D. and F.
E. Clayton, Eds., Patty's Industrial Hygiene and Toxicology, 3rd. ed., Vol. 2A. John Wiley and
Sons, New York, NY, pp. 2469-2434.
Beauchamp, R.O., Jr., R.D. Irons, D.E. Rickert, D.B. Couch and T.E. Hamm, Jr. 1982. A critical
review of the literature on nitrobenzene toxicity. CRC Crit. Rev. Toxicol. 11: 33-84.
Bond, J.A., J.P. Chism, D.E. Rickert and J.A. Popp. 1981. Induction of hepatic and testicular
lesions in Fischer-344 rats by single oral doses of nitrobenzene. Fund. Appl. Toxicol. 1: 389-394.
CIIT (Chemical Industry Institute of Toxicology). 1984. Ninety-day inhalation toxicity study of
nitrobenzene in F-344 Rats, CD Rats, and B6C3F1 Mice. Chemical Industry Institute of Toxicology,
Research Triangle Park, NC. (Cited in U.S. EPA, 1980, 1992a,b; ATSDR, 1990)
Dodd, D.E., E.H. Fowler, W.M. Snellings, et al. 1987. Reproduction and fertility evaluations in CD
rats following nitrobenzene inhalation. Fundam. Appl. Toxicol. 8: 493-505.
Dorigan, J. and J. Hushon. 1976. Air pollution assessment of nitrobenzene. U.S. Environmental
Protection Agency. (Cited in U.S. EPA, 1980)
Dunlap, K.L. 1981. Nitrobenzene and nitrotoluenes. In: M. Grayson and D. Eckroth, Eds., Kirk-Othmer Encyclopedia of Chemical Technology, 3rd. ed., Vol. 15. John Wiley and Sons, New York,
NY, pp. 916-925.
Goldstein, R.S., J.P. Chism, J.M. Sherill and T.E. Hamm, Jr. 1984. Influence of dietary pectin on
intestinal microfloral metabolism and toxicity of nitrobenzene. Toxicol. Appl. Pharmacol. 75: 547-553.
Ikeda, M. and A. Kita. 1964. Excretion of p-nitrophenol and p-aminophenol in the urine of a patient
exposed to nitrobenzene. Br. J. Ind. Med. 21: 210-213.
Kazanina, S.S. 1968. The morphology and histochemistry of hemochorial placentas of rats after
nitrobenzene intoxication of the mother. Bull. Exp. Biol. Med. (USSR) 65: 93-96. [CA 69(17):
65819t] (Cited in U.S. EPA, 1985)
Levin, A.A., T. Bosakowski, L.L. Earle and B.E. Butterworth. 1988. The reversibility of
nitrobenzene-induced testicular toxicity: Continuous monitoring of sperm output from
vasocystotomized rats. Toxicology 53: 219-230.
Medinsky, M.A. and R.D. Irons. 1985. Sex, strain, and species differences in the response to
nitrobenzene vapors. In: Rickert, D.E., Ed., Chemical Industry Institute of Toxicology Series.
Toxicity of nitroaromatic compounds. Hemisphere Publishing Corporation, New York, NY, pp. 35-51. Morgan, K.T., E.A. Gross, O. Lyght, et al. 1985. Morphologic and biochemical studies of a
nitrobenzene-induced encephalopathy in rats. Neurotoxicology 6: 105-116. (Cited in ATSDR,
1990)
OSHA (Occupational Safety and Health Administration). 1978. Occupational Health Guideline for
Nitrobenzene. U.S. Department of Health and Human Services. (Cited in U.S. EPA, 1985)
Parke, D.V. 1956. Studies in detoxication: The metabolism of [14C]nitrobenzene in the rabbit and
guinea pig. Biochem. J. 62: 339-346.
Piotrowski, J. 1967. Further investigations on the evaluation of exposure to nitrobenzene. Br. J.
Ind. Med. 24: 60-67. (Cited in U.S. EPA, 1980)
Piotrowski, J. 1977. Exposure tests for organic compounds in industrial toxicology. NIOSH 77-144. U.S. Department of Health and Human Services. (Cited in U.S EPA, 1980)
Rickert, D.E., J.A. Bond, R.M. Long and J.P. Chism. 1983. Metabolism and excretion of
nitrobenzene by rats and mice. Toxicol. Appl. Pharmacol. 67: 206-214.
Salmova, J., J. Piotrowski and U. Neuhorn. 1963. Evaluation of exposure to nitrobenzene:
Absorption of nitrobenzene vapour through lungs and excretion of p-nitrophenol in urine. Br. J. Ind.
Med. 20: 41-46. (Cited in ATSDR, 1990)
Shimkin, M.B. 1939. Acute toxicity of mononitrobenzene in mice. Proc. Soc. Exp. Biol. Med. 42:
844-846. (Cited in ATSDR, 1990)
Smyth, H.F., Jr., C.S. Weil, J.S. West, et al. 1969. An exploration of joint toxic action: Twenty-seven industrial chemicals intubated in rats in all possible pairs. Toxicol. Appl. Pharmacol. 14: 340-347.
Tyl, R.W., K.A. France, L.C. Fisher, et al. 1987. Developmental toxicity evaluation of inhaled
nitrobenzene in CD rats. Fundam. Appl. Toxicol. 8: 482-492.
U.S. EPA. 1980. Ambient Water Quality Criteria for Nitrobenzene. Office of Water Regulations
and Standards, Criteria and Standards Division Washington, DC. EPA 440/5-80-061. NTIS PB81-117723.
U.S. EPA. 1985. Health and Environmental Effects Profile for Nitrobenzene. Prepared by the
Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office,
Cincinnati, OH, for the Office of Emergency and Remedial Response, Washington, DC. ECAO-CIN-P145.
U.S. EPA. 1992a. Nitrobenzene. Integrated Risk Information System (IRIS). Environmental
Criteria and Assessment Office, Office of Health and Environmental Assessment, Cincinnati, OH.
U.S. EPA. 1992b. Health Assessment Summary Tables. Annual FY-92. Prepared by the Office
of Health and Environmental Assessment, Environmental Criteria and Assessment Office,
Cincinnati, OH, for the Office of Emergency and Remedial Response, Washington, DC.
Yamada, Y. 1958. Studies on the experimental chronic poisoning of nitrobenzene. Kobe J. Med.
Sci. 4: 427. (Cited in U.S. EPA, 1980)
Retrieve Toxicity Profiles
Condensed Version
Last Updated 8/29/97
|